CL2014001389A1 - Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing. - Google Patents
Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing.Info
- Publication number
- CL2014001389A1 CL2014001389A1 CL2014001389A CL2014001389A CL2014001389A1 CL 2014001389 A1 CL2014001389 A1 CL 2014001389A1 CL 2014001389 A CL2014001389 A CL 2014001389A CL 2014001389 A CL2014001389 A CL 2014001389A CL 2014001389 A1 CL2014001389 A1 CL 2014001389A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydroisoquinolin
- prophylaxis
- hypertension
- treatment
- pharmaceutical composition
- Prior art date
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 208000016998 Conn syndrome Diseases 0.000 title 1
- 208000014311 Cushing syndrome Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000013846 primary aldosteronism Diseases 0.000 title 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011083229 | 2011-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001389A1 true CL2014001389A1 (es) | 2014-10-03 |
Family
ID=47297189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001389A CL2014001389A1 (es) | 2011-11-30 | 2014-05-27 | Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9133158B2 (es) |
| EP (2) | EP3587401A1 (es) |
| JP (1) | JP6382108B2 (es) |
| KR (1) | KR102089927B1 (es) |
| AR (1) | AR088989A1 (es) |
| AU (1) | AU2012344041B2 (es) |
| BR (1) | BR112014013136B1 (es) |
| CA (1) | CA2850700C (es) |
| CL (1) | CL2014001389A1 (es) |
| CO (1) | CO6920296A2 (es) |
| CR (1) | CR20140229A (es) |
| DK (1) | DK2785695T3 (es) |
| EA (1) | EA035454B1 (es) |
| ES (1) | ES2811806T3 (es) |
| HR (1) | HRP20201277T1 (es) |
| HU (1) | HUE050431T2 (es) |
| IL (1) | IL232570B (es) |
| LT (1) | LT2785695T (es) |
| MA (1) | MA35664B1 (es) |
| MX (1) | MX350717B (es) |
| MY (1) | MY178867A (es) |
| PE (1) | PE20141283A1 (es) |
| PH (1) | PH12014501179B1 (es) |
| PL (1) | PL2785695T3 (es) |
| PT (1) | PT2785695T (es) |
| RS (1) | RS60660B1 (es) |
| SG (1) | SG11201402199QA (es) |
| SI (1) | SI2785695T1 (es) |
| TW (1) | TWI583678B (es) |
| UA (1) | UA112565C2 (es) |
| WO (1) | WO2013079452A1 (es) |
| ZA (1) | ZA201402908B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP2989082A1 (en) * | 2013-04-23 | 2016-03-02 | LEK Pharmaceuticals d.d. | Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof |
| CN105209470B (zh) * | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| JP6581970B2 (ja) * | 2013-05-27 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| MY176401A (en) | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| PE20171057A1 (es) * | 2014-10-08 | 2017-07-21 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| AP2017009829A0 (en) * | 2014-10-15 | 2017-03-31 | Boehringer Ingelheim Int | Aldosterone synthase inhibitors |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| WO2016089800A1 (en) * | 2014-12-02 | 2016-06-09 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP3381904B1 (en) * | 2015-10-23 | 2021-07-28 | Mitsubishi Tanabe Pharma Corporation | Novel nitrogen-containing aromatic heterocyclic compound |
| AU2016379292B2 (en) | 2015-12-24 | 2021-03-25 | Kyowa Kirin Co., Ltd. | α, β unsaturated amide compound |
| EP3509588B1 (en) | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Bicyclic compounds useful as gpr120 modulators |
| WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| WO2018235926A1 (ja) | 2017-06-23 | 2018-12-27 | 協和発酵キリン株式会社 | α、β不飽和アミド化合物 |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| CN109810171B (zh) * | 2017-11-21 | 2020-12-01 | 首都医科大学 | 二氢异喹啉-3-甲酰-LARGD(aa)aa,其制备,抗静脉血栓活性和应用 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| CN111051309B (zh) * | 2018-06-26 | 2023-05-26 | 浙江春禾医药科技有限公司 | 可用作a2a受体拮抗剂的三唑并三嗪衍生物 |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| JP7530384B2 (ja) | 2019-05-01 | 2024-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート |
| WO2021032935A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| US12213973B2 (en) | 2021-10-18 | 2025-02-04 | Northwestern University | Bacterial nitric oxide synthase inhibitors |
| CA3236890A1 (en) | 2021-12-14 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors for treating chronic kidney disease |
| EP4574830A4 (en) * | 2022-09-23 | 2025-11-26 | Guangzhou Vinnocent Pharmaceutical Ltd | PYRIDINE INHIBITOR, RINGED STEROID SYNTHETASE, ITS PREPARATION PROCESS AND ITS USE |
| AU2023378302A1 (en) * | 2022-11-10 | 2025-04-10 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| CN117247371B (zh) * | 2023-09-18 | 2026-03-10 | 上海相辉医药科技有限公司 | 一种cyp11b2抑制剂baxdrostat的制备方法 |
| CN121135736A (zh) * | 2024-03-01 | 2025-12-16 | 浙江扬厉医药技术有限公司 | 吡喃并吡啶类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT79699B (en) | 1983-12-22 | 1986-12-10 | Pfizer | Process for preparing quinolone inotropic agents |
| AU2002306596B2 (en) * | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2007117982A2 (en) * | 2006-03-29 | 2007-10-18 | Novartis Ag | Organic compounds |
| JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2430011A1 (en) * | 2009-05-15 | 2012-03-21 | Novartis AG | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1 |
| US8946260B2 (en) * | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
-
2012
- 2012-11-27 BR BR112014013136-8A patent/BR112014013136B1/pt not_active IP Right Cessation
- 2012-11-27 EP EP19187075.7A patent/EP3587401A1/en active Pending
- 2012-11-27 MY MYPI2014701399A patent/MY178867A/en unknown
- 2012-11-27 PE PE2014000766A patent/PE20141283A1/es active IP Right Grant
- 2012-11-27 HR HRP20201277TT patent/HRP20201277T1/hr unknown
- 2012-11-27 DK DK12797817.9T patent/DK2785695T3/da active
- 2012-11-27 AU AU2012344041A patent/AU2012344041B2/en not_active Ceased
- 2012-11-27 CA CA2850700A patent/CA2850700C/en active Active
- 2012-11-27 KR KR1020147018023A patent/KR102089927B1/ko not_active Expired - Fee Related
- 2012-11-27 JP JP2014543854A patent/JP6382108B2/ja active Active
- 2012-11-27 SI SI201231822T patent/SI2785695T1/sl unknown
- 2012-11-27 MX MX2014005833A patent/MX350717B/es active IP Right Grant
- 2012-11-27 LT LTEP12797817.9T patent/LT2785695T/lt unknown
- 2012-11-27 AR ARP120104439A patent/AR088989A1/es active IP Right Grant
- 2012-11-27 RS RS20200979A patent/RS60660B1/sr unknown
- 2012-11-27 WO PCT/EP2012/073653 patent/WO2013079452A1/en not_active Ceased
- 2012-11-27 EP EP12797817.9A patent/EP2785695B1/en active Active
- 2012-11-27 EA EA201491018A patent/EA035454B1/ru not_active IP Right Cessation
- 2012-11-27 SG SG11201402199QA patent/SG11201402199QA/en unknown
- 2012-11-27 ES ES12797817T patent/ES2811806T3/es active Active
- 2012-11-27 PL PL12797817T patent/PL2785695T3/pl unknown
- 2012-11-27 UA UAA201407120A patent/UA112565C2/uk unknown
- 2012-11-27 HU HUE12797817A patent/HUE050431T2/hu unknown
- 2012-11-27 PT PT127978179T patent/PT2785695T/pt unknown
- 2012-11-29 US US13/688,373 patent/US9133158B2/en active Active
- 2012-11-29 TW TW101144851A patent/TWI583678B/zh not_active IP Right Cessation
-
2014
- 2014-03-31 CO CO14068498A patent/CO6920296A2/es active IP Right Grant
- 2014-04-22 ZA ZA2014/02908A patent/ZA201402908B/en unknown
- 2014-05-12 IL IL232570A patent/IL232570B/en active IP Right Grant
- 2014-05-15 CR CR20140229A patent/CR20140229A/es unknown
- 2014-05-26 PH PH12014501179A patent/PH12014501179B1/en unknown
- 2014-05-27 CL CL2014001389A patent/CL2014001389A1/es unknown
- 2014-05-27 MA MA37074A patent/MA35664B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001389A1 (es) | Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing. | |
| CL2014000604A1 (es) | Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. | |
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014001779A1 (es) | Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014000504A1 (es) | Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
| EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
| CL2014000459A1 (es) | Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar. | |
| BR112014010183A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| HUE055286T2 (hu) | Pirimidinszármazékok vírusfertõzések kezelésére | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| CL2013003686A1 (es) | Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| CL2014000819A1 (es) | Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo. | |
| AR088971A1 (es) | INHIBIDOR DE a₁-PROTEINASA PARA DEMORAR EL COMIENZO O PROGRESION DE EXACERBACIONES PULMONARES | |
| LT2939665T (lt) | Farmacinė kompozicija, skirta živ infekcijų gydymui |